T. Rowe Price Associates’s Alaunos Therapeutics TCRT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-813
| Closed | -$63K | – | 2913 |
|
|
2023
Q2 | $63K | Sell |
813
-93
| -10% | -$7.52K | ﹤0.01% | 2773 |
|
|
2023
Q1 | $86K | Buy |
906
+316
| +54% | +$30.1K | ﹤0.01% | 2713 |
|
|
2022
Q4 | $57K | Hold |
590
| – | – | ﹤0.01% | 2795 |
|
|
2022
Q3 | $153K | Sell |
590
-73
| -11% | -$21.2K | ﹤0.01% | 2624 |
|
|
2022
Q2 | $123K | Sell |
663
-216
| -25% | -$20.6K | ﹤0.01% | 2717 |
|
|
2022
Q1 | $86K | Buy |
879
+119
| +16% | +$15.3K | ﹤0.01% | 2871 |
|
|
2021
Q4 | $124K | Sell |
760
-776
| -51% | -$171K | ﹤0.01% | 2845 |
|
|
2021
Q3 | $419K | Buy |
1,536
+850
| +124% | +$260K | ﹤0.01% | 2455 |
|
|
2021
Q2 | $272K | Buy |
686
+55
| +9% | +$25.7K | ﹤0.01% | 2625 |
|
|
2021
Q1 | $341K | Sell |
631
-89
| -12% | -$55.4K | ﹤0.01% | 2521 |
|
|
2020
Q4 | $272K | Sell |
720
-5
| -0.7% | -$1.99K | ﹤0.01% | 2459 |
|
|
2020
Q3 | $274K | Hold |
725
| – | – | ﹤0.01% | 2324 |
|
|
2020
Q2 | $357K | Buy |
725
+15
| +2% | +$6.69K | ﹤0.01% | 2188 |
|
|
2020
Q1 | $261K | Buy |
710
+27
| +4% | +$14K | ﹤0.01% | 2240 |
|
|
2019
Q4 | $484K | Buy |
683
+60
| +10% | +$41.3K | ﹤0.01% | 2160 |
|
|
2019
Q3 | $400K | Buy |
623
+5
| +0.8% | +$3.97K | ﹤0.01% | 2182 |
|
|
2019
Q2 | $540K | Buy |
618
+5
| +0.8% | +$3.44K | ﹤0.01% | 2084 |
|
|
2019
Q1 | $354K | Buy |
613
+3
| +0.5% | +$1.25K | ﹤0.01% | 2242 |
|
|
2018
Q4 | $171K | Sell |
610
-100
| -14% | -$39.5K | ﹤0.01% | 2436 |
|
|
2018
Q3 | $341K | Buy |
710
+194
| +38% | +$83.2K | ﹤0.01% | 2309 |
|
|
2018
Q2 | $234K | Buy |
516
+6
| +1% | +$3.81K | ﹤0.01% | 2416 |
|
|
2018
Q1 | $300K | Buy |
510
+140
| +38% | +$87.3K | ﹤0.01% | 2294 |
|
|
2017
Q4 | $230K | Sell |
370
-78
| -17% | -$56K | ﹤0.01% | 2376 |
|
|
2017
Q3 | $412K | Buy |
448
+104
| +30% | +$92.4K | ﹤0.01% | 2163 |
|
|
2017
Q2 | $321K | Sell |
344
-91
| -21% | -$89.2K | ﹤0.01% | 2222 |
|
|
2017
Q1 | $414K | Hold |
435
| – | – | ﹤0.01% | 2134 |
|
|
2016
Q4 | $349K | Hold |
435
| – | – | ﹤0.01% | 2196 |
|
|
2016
Q3 | $367K | Hold |
435
| – | – | ﹤0.01% | 2137 |
|
|
2016
Q2 | $358K | Buy |
435
+86
| +25% | +$93.6K | ﹤0.01% | 2099 |
|
|
2016
Q1 | $388K | Hold |
349
| – | – | ﹤0.01% | 2070 |
|
|
2015
Q4 | $435K | Sell |
349
-268
| -43% | -$443K | ﹤0.01% | 2017 |
|
|
2015
Q3 | $833K | Buy |
617
+72
| +13% | +$119K | ﹤0.01% | 1761 |
|
|
2015
Q2 | $982K | Buy |
545
+210
| +63% | +$326K | ﹤0.01% | 1753 |
|
|
2015
Q1 | $541K | Sell |
335
-86
| -20% | -$127K | ﹤0.01% | 1946 |
|
|
2014
Q4 | $320K | Hold |
421
| – | – | ﹤0.01% | 2146 |
|
|
2014
Q3 | $167K | Buy |
421
+134
| +47% | +$64.6K | ﹤0.01% | 2386 |
|
|
2014
Q2 | $173K | Hold |
287
| – | – | ﹤0.01% | 2393 |
|
|
2014
Q1 | $197K | Hold |
287
| – | – | ﹤0.01% | 2329 |
|
|
2013
Q4 | $187K | Buy |
+287
| New | +$171K | ﹤0.01% | 2329 |
|
Other funds holding TCRT
DCM
MP
BC
GCP
CB
T. Rowe Price Associates's TCRT Position: Q3 2023 in Review
T. Rowe Price Associates sold out of Alaunos Therapeutics (TCRT) in Q3 2023, closing a stake of 813 shares — an estimated $63K sold.
T. Rowe Price Associates first reported a position in TCRT in Q4 2013 and held it in 39 quarters. The position peaked at $982K in Q2 2015. 89 funds tracked by Wall St. Rank hold TCRT as of Q3 2023.
- T. Rowe Price Associates reported no remaining Alaunos Therapeutics position as of Q3 2023 after selling out during the quarter.
- T. Rowe Price Associates sold 813 Alaunos Therapeutics shares in Q3 2023, an estimated $63K.
- T. Rowe Price Associates first reported a position in Alaunos Therapeutics in Q4 2013 and held it in 39 quarters.
- T. Rowe Price Associates's Alaunos Therapeutics position peaked at $982K in Q2 2015.
- 89 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q3 2023.
Based on T. Rowe Price Associates's 13F filing for Q3 2023, filed 14 Nov 2023.